title: Resected colorectal liver metastases: does the survival differ according to postoperative chemotherapy regimen?
abstract: OBJECTIVE
  We compared clinical outcomes in patients who were treated with different chemotherapeutic regimens after resection of hepatic metastases from colorectal cancer (CRC).
  
  
  METHODS
  Between August 2001 and June 2008, 156 patients who entered into chemotherapy of adjuvant intent after hepatic metastasectomy were reviewed retrospectively.
  
  
  RESULTS
  Of the 156 patients, 58 patients were treated with oxaliplatin/fluoropyrimidines (group I), 48 with irinotecan/fluoropyrimidines (group II), and 50 with fluoropyrimidines alone (group III). In the univariate analysis, there was a marginally significant difference among the three groups with respect to the disease-free survival (DFS); 23.4 months in group I, 14.1 months in group II, and 16.3 months in group III, P = 0.088). Group I showed better DFS when compared to the other two groups combined (group II and III) (P = 0.03). Multivariable analysis showed a marginally significant gain in the DFS for group I (P = 0.068). Multiple metastases (P = 0.045) and positive resection margin (P = 0.003) were significantly associated with poorer DFS.
  
  
  CONCLUSIONS
  Postoperative combination chemotherapy of oxaliplatin/fluoropyrimidines seemed to show better DFS when compared to fluoropyrimidine monotherapy or irinotecan-based combination in patients who underwent liver metastasectomy.
authors.affiliation: Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea.
authors.forename: Sun Young
authors.initials: SY
authors.lastname: Kim
authors.forename: Hee Jun
authors.initials: HJ
authors.lastname: Kim
authors.forename: Yong Sang
authors.initials: YS
authors.lastname: Hong
authors.forename: Kyung Hae
authors.initials: KH
authors.lastname: Jung
authors.forename: Ji Won
authors.initials: JW
authors.lastname: Park
authors.forename: Hyo Seong
authors.initials: HS
authors.lastname: Choi
authors.forename: Jae Hwan
authors.initials: JH
authors.lastname: Oh
authors.forename: Sang-Jae
authors.initials: SJ
authors.lastname: Park
authors.forename: Seong Hoon
authors.initials: SH
authors.lastname: Kim
authors.forename: Byung-Ho
authors.initials: BH
authors.lastname: Nam
authors.forename: Hee Jin
authors.initials: HJ
authors.lastname: Chang
authors.forename: Dae Yong
authors.initials: DY
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies